Aldose reductase inhibitors for the treatment of diabetic polyneuropathy.

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Cochrane Database of Systematic Reviews

• Publication date

  2007-10-17

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/14651858.CD004572.PUB2PMID 17943821PMCID PMC8406996
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Placebo

  2007cited by this paper
• Three‐year inhibition of aldose reductase on development of symptomatic neuropathy in diabetic patients

  2006cited by this paper
• Treatment of Diabetic Polyneuropathy

  2006cited by this paper
• Mechanisms of Disease: mitochondria as new therapeutic targets in diabetic neuropathy

  2006cited by this paper
• Long-Term Clinical Effects of Epalrestat, an Aldose Reductase Inhibitor, on Diabetic Peripheral Neuropathy

  2006cited by this paper
• Long-term effects of ranirestat (AS-3201) on peripheral nerve function in patients with diabetic sensorimotor polyneuropathy.

  2006cited by this paper
• Treatment of diabetic autonomic neuropathy with an aldose reductase inhibitor

  2004cited by this paper
• Natural progression of diabetic peripheral neuropathy in the Zenarestat study population.

  2004cited by this paper
• Cardiac abnormalities in diabetic patients with neuropathy: effects of aldose reductase inhibitor administration.

  2004cited by this paper
• Clinical Potential of Aldose Reductase Inhibitors in Diabetic Neuropathy

  2004cited by this paper
• Textbook of Diabetic Neuropathy

  2002cited by this paper
• Polyol pathway and diabetic peripheral neuropathy.

  2002cited by this paper
• Aldose reductase inhibition ameliorates pupillary light reflex and F-wave latency in patients with mild diabetic neuropathy.

  2001cited by this paper
• Clinical efficacy of fidarestat, a novel aldose reductase inhibitor, for diabetic peripheral neuropathy: a 52-week multicenter placebo-controlled double-blind parallel group study.

  2001cited by this paper
• Effect of aldose reductase inhibition on nerve conduction and morphometry in diabetic neuropathy

  1999cited by this paper
• Preventive Foot Care in People With Diabetes

  1998cited by this paper
• Bias in meta›analysis detected by a simple, graphical test

  1998cited by this paper
• Multicenter Study of the Incidence of and Predictive Risk Factors for Diabetic Neuropathic Foot Ulceration

  1998cited by this paper
• Preventive Foot Care in People With Diabetes

  1998cited by this paper
• Longitudinal assessment of diabetic polyneuropathy using a composite score in the Rochester Diabetic Neuropathy Study cohort

  1997cited by this paper
• Bias in meta-analysis detected by a simple, graphical test

  1997cited by this paper
• Metabolic and Vascular Factors in the Pathogenesis of Diabetic Neuropathy

  1997cited by this paper
• A Meta‐analysis of Trials on Aldose Reductase Inhibitors in Diabetic Peripheral Neuropathy

  1996cited by this paper
• Aldose reductase inhibitors for the prevention and treatment of diabetic peripheral neuropathy.

  1996cited by this paper
• [Tolrestat in the therapy of diabetic peripheral neuropathy: is this drug really useful?].

  1995cited by this paper
• Effect of Tolrestat on oesophageal transit time and cholecystic motility in type 2 diabetic patients with asymptomatic diabetic neuropathy.

  1995cited by this paper
• Tolrestat in the Primary Prevention of Diabetic Neuropathy

  1995cited by this paper
• DER EINFLUSS DES ALDOSE-REDUKTASE-INHIBITORS PONALRESTAT AUF DIE DIABETISCHE POLYNEUROPATHIE : EINE EINJAHRIGE DOPPELBLINDSTUDIE

  1994cited by this paper
• A Placebo‐controlled Double‐blind Study of Epalrestat (ONO‐2235) in Patients with Diabetic Neuropathy

  1993cited by this paper
• Effect of hyperglycemia and the aldose reductase inhibitor tolrestat on sural nerve biochemistry and morphometry in advanced diabetic peripheral polyneuropathy. The Tolrestat Study Group.

  1993cited by this paper
• Tolrestat for Mild Diabetic Neuropathy: A 52-Week, Randomized, Placebo-Controlled Trial

  1993cited by this paper
• Further clinical studies with an aldose reductase inhibitor in diabetic neuropathy.

  1993cited by this paper
• [Treatment with an aldose reductase inhibitor in peripheral neuropathy in elderly diabetic patients].

  1993cited by this paper
• The sorbinil retinopathy trial: neuropathy results. Sorbinil Retinopathy Trial Research Group.

  1993cited by this paper
• Withdrawal of the aldose reductase inhibitor tolrestat in patients with diabetic neuropathy: effect on nerve function. The Tolrestat Study Group.

  1993cited by this paper
• The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus.

  1993cited by this paper
• Further Clinical Studies with an Aldose Reductase Inhibitor in Diabetic Neuropathy

  1993influential reference
• A multicentre trial of the aldose-reductase inhibitor tolrestat, in patients with symptomatic diabetic peripheral neuropathy. North European Tolrestat Study Group.

  1992cited by this paper
• A 12‐Month Randomized Controlled Study of the Aldose Reductase Inhibitor Ponalrestat in Patients with Chronic Symptomatic Diabetic Neuropathy

  1992cited by this paper
• Long-term effects of tolrestat on symptomatic diabetic sensory polyneuropathy.

  1992cited by this paper
• Peripheral and autonomic nerve function in 259 diabetic patients with peripheral neuropathy treated with ponalrestat (an aldose reductase inhibitor) or placebo for 18 months. United Kingdom/Scandinavian Ponalrestat Trial.

  1992cited by this paper
• Clinical and Neurophysiological Studies of Aldose Reductase Inhibitor Ponalrestat in Chronic Symptomatic Diabetic Peripheral Neuropathy

  1991cited by this paper
• A double blind controlled study on the effect of tolrestat on diabetic autonomic neuropathy

  1991cited by this paper
• One-year treatment with the aldose reductase inhibitor, ponalrestat, in diabetic neuropathy.

  1991cited by this paper
• Prolonged Aldose Reductase Inhibition in Chronic Peripheral Diabetic Neuropathy: Effects on Microangiopathy

  1990cited by this paper
• A multicentre trial of the aldose-reductase inhibitor, tolrestat, in patients with symptomatic diabetic neuropathy

  1990cited by this paper
• Hypoxic neuropathy Does hypoxia play a role in diabetic neuropathy?

  1989cited by this paper
• Diabetic neuropathy in the upper limb and the effect of twelve months sorbinil treatment

  1988cited by this paper
• Aldose Reductase Inhibition in Diabetic Neuropathy: Clinical and Neurophysiological Studies of one Year's Treatment with Sorbinil

  1988cited by this paper
• Regeneration and repair of myelinated fibers in sural-nerve biopsy specimens from patients with diabetic neuropathy treated with sorbinil.

  1988cited by this paper
• [Diabetic neuropathy: treatment trial with an aldose reductase inhibitor (Sorbinil)].

  1987cited by this paper
• Six-Month Treatment with Sorbinil in Asymptomatic Diabetic Neuropathy: Failure to Improve Abnormal Nerve Function

  1987cited by this paper
• Neurophysiological variables and fibrinolysis in insulin-dependent diabetes treated with an aldose reductase inhibitor or placebo. A double-blind randomized study.

  1986cited by this paper
• Limited benefit of treatment of diabetic polyneuropathy with an aldose reductase inhibitor: a 24-week controlled trial

  1985cited by this paper
• Effects of cyclandelate on diabetic peripheral neuropathy.

  1984cited by this paper
• Treatment of severely painful diabetic neuropathy with an aldose reductase inhibitor: relief of pain and improved somatic and autonomic nerve function.

  1983cited by this paper
• A Controlled Trial of Sorbinil, an Aldose Reductase Inhibitor, in Chronic Painful Diabetic Neuropathy

  1983cited by this paper
• Effects of aldose reductase inhibitor treatment in diabetic polyneuropathy - a clinical and neurophysiological study.

  1981cited by this paper
• A Coefficient of Agreement for Nominal Scales

  1960cited by this paper

• Wound, pressure ulcer, and burn guidelines – 3: Guidelines for the diagnosis and treatment of diabetic ulcers and gangrene, second edition

  2025cites this paper
• Computational Screening of Bioactive Compounds of Gymnema sylvestre for ALR2 Inhibition: A Virtual Screening Approach

  2025cites this paper
• Intradermal Advanced Glycation End-products Relate to Reduced Sciatic Nerve Structural Integrity in Type 2 Diabetes

  2025cites this paper
• Study of Pineapple Bioactive Compounds Targeting Aldose Reductase: A Natural Intervention for Diabetes Mellitus Pathologies

  2025influential citation
• Early Diagnosis of Diabetic Neuropathy: A Review of Current Diagnostic Tests

  2025cites this paper
• Current advances in diabetic neuropathy: Proteins as therapeutic targets

  2025cites this paper
• Crumbling Pathogenesis and Biomarkers for Diabetic Peripheral Neuropathy

  2025cites this paper
• Aucubin mitigates the elevation of microglial aerobic glycolysis and inflammation in diabetic neuropathic pain via aldose reductase

  2025cites this paper
• GC-MS Profiling of Ethanol-Extracted Polyherbal Compounds from Medicinal Plant (Citrullus colocynthis, Curcuma longa, and Myristica fragrans): In Silico and Analytical Insights into Diabetic Neuropathy Therapy via Targeting the Aldose Reductase

  2025cites this paper
• Danshenol B alleviates central post-stroke pain by regulating the PIK3CG/NLRP3 signaling pathway

  2025cites this paper
• AKR1B1 bridges metabolic pathways and disease progression.

  2025cites this paper
• Plant-Based Diets and Phytochemicals in the Management of Diabetes Mellitus and Prevention of Its Complications: A Review

  2024cites this paper
• Alpha-lipoic acid for diabetic peripheral neuropathy.

  2024cites this paper
• Serum SARM1 Levels and Diabetic Peripheral Neuropathy in Type 2 Diabetes: Correlation with Clinical Neuropathy Scales and Nerve Conduction Studies and Impact of COVID-19 vaccination

  2024cites this paper
• Update on Treating Painful Diabetic Peripheral Neuropathy: A Review of Current US Guidelines with a Focus on the Most Recently Approved Management Options

  2024cites this paper
• Neuropatie nei diabetici

  2024cites this paper
• Novel drugs affecting diabetic peripheral neuropathy

  2024cites this paper
• Risks of carpal tunnel syndrome and carpal tunnel release surgery in users of sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists: a target trial emulation study.

  2024cites this paper
• Acupoint prescriptions,treatment protocol and outcome evidence for acupuncture in diabetic peripheral neuropathy: A scoping review of clinical studies

  2024cites this paper
• Selectivity Challenges for Aldose Reductase Inhibitors: A Review on Comparative SAR and Interaction Studies

  2024cites this paper
• Exploring aldose reductase inhibitors as promising therapeutic targets for diabetes-linked disabilities.

  2024cites this paper
• Mitochondrial dysfunction in diabetic neuropathy: Impaired mitophagy triggers NLRP3 inflammasome.

  2024cites this paper
• Neuropathies chez les diabétiques

  2024cites this paper
• Cutaneous Carbonyl Stress Is Associated With Nerve Dysfunction in Recent-Onset Type 2 Diabetes.

  2024cites this paper
• Promise of the gut microbiota in prevention and traditional Chinese medicine treatment of diabetic peripheral neuropathy

  2024cites this paper
• Diabetic complications and prospective immunotherapy

  2023cites this paper
• Tracer metabolomics reveals the role of aldose reductase in glycosylation

  2023cites this paper
• Diabetic Polyneuropathy: New Strategies to Target Sensory Neurons in Dorsal Root Ganglia

  2023cites this paper
• Homoeopathic treatment on diabetic distal symmetric polyneuropathy [ddsp]: a systematic review.

  2023cites this paper
• Natural molecules as promising players against diabetic peripheral neuropathy: an emerging nutraceutical approach

  2023cites this paper
• The role of aldose reductase in polyol pathway: An emerging pharmacological target in diabetic complications and associated morbidities.

  2023cites this paper
• Treatment of diabetic complications: do flavonoids holds the keys?

  2023cites this paper
• Diabetic corneal neuropathy as a surrogate marker for diabetic peripheral neuropathy

  2022cites this paper
• Diabetic neuropathy

  2022cites this paper
• The impact of canagliflozin on the risk of neuropathy events: a post-hoc exploratory analysis of the CREDENCE trial.

  2022cites this paper
• An Insight into Potential Pharmacotherapeutic Agents for Painful Diabetic Neuropathy

  2022cites this paper
• The Role of Aldose Reductase in Beta-Amyloid-Induced Microglia Activation

  2022cites this paper
• Phenylacetylglutamine as a novel biomarker of type 2 diabetes with distal symmetric polyneuropathy by metabolomics

  2022cites this paper
• Diabetic Peripheral Neuropathy.

  2022cites this paper
• Motor neuron survival is associated with reduced neuroinflammation and increased autophagy after brachial plexus avulsion injury in aldose reductase-deficient mice

  2022cites this paper
• Is Nerve Electrophysiology a Robust Primary Endpoint in Clinical Trials of Treatments for Diabetic Peripheral Neuropathy?

  2022cites this paper
• Pathogenesis of Distal Symmetrical Polyneuropathy in Diabetes

  2022cites this paper
• Diabetic neuropathy: A narrative review of risk factors, classification, screening and current pathogenic treatment options (Review)

  2021cites this paper
• Diabetes and the Nervous System

  2021cites this paper
• Novel treatment modalities for painful diabetic neuropathy.

  2021cites this paper
• Diagnostic tools, biomarkers, and treatments in diabetic polyneuropathy and cardiovascular autonomic neuropathy.

  2021cites this paper
• Pathogenesis, diagnosis and clinical management of diabetic sensorimotor peripheral neuropathy

  2021cites this paper
• Study of Epalrestat in Diabetic Distal Symmetric Polyneuropathy and correlation of its therapeutic efficacy with erythrocyte sorbitol levels : A step towards Precision Medicine

  2021cites this paper
• Management of diabetic neuropathy.

  2021cites this paper
• Ultra Performance Liquid Chromatography-Quadrupole Time-of-Flight Mass Spectrometry (UPLC-Q-TOF-MS)-based metabolomic analysis of mycelial biomass of three Ganoderma isolates from the Lower Volta River Basin of Ghana.

  2021cites this paper
• Magnetic Resonance Imaging as a Biomarker in Diabetic and HIV-Associated Peripheral Neuropathy: A Systematic Review-Based Narrative

  2021cites this paper
• Axonal Charcot-Marie-Tooth Disease: from Common Pathogenic Mechanisms to Emerging Treatment Opportunities

  2021cites this paper
• Physiological and Pathological Roles of Aldose Reductase

  2021cites this paper
• The Application of Exercise Training for Diabetic Peripheral Neuropathy

  2021cites this paper
• Intracellular Metabolism in Diabetic Embryopathy

  2021cites this paper
• Diabetic Foot – Research

  2020cites this paper
• Inactive matrix gla protein plasma levels are associated with peripheral neuropathy in Type 2 diabetes

  2020cites this paper
• Treating Pain in Diabetic Neuropathy: Current and Developmental Drugs

  2020cites this paper
• Challenges of neuropathic pain: focus on diabetic neuropathy

  2020cites this paper
• References

  2020cites this paper
• Mechanisms of Diabetic Neuropathies and Antioxidant Therapy

  2020cites this paper
• Structure based peptide design, molecular dynamics and MM-PBSA studies for targeting C terminal dimerization of NFAT5 DNA binding domain.

  2020cites this paper
• Systematic review on anti-diabetic properties of chalcones.

  2020cites this paper
• Pathophysiology

  2020cites this paper
• What are neuropathies?

  2020cites this paper
• Development of aldose reductase inhibitors for the treatment of inflammatory disorders and cancer: current drug design strategies and future directions.

  2020cites this paper
• Current concepts in the management of diabetic polyneuropathy

  2020cites this paper
• Diabetic Peripheral Neuropathy: Diagnosis and Treatment.

  2020cites this paper
• Diabetic neuropathies

  2020influential citation
• Diabetic polyneuropathy: Bridging the translational gap

  2020cites this paper
• Screening inhibitory effects of selected flavonoids on human recombinant aldose reductase enzyme: in vitro and in silico study

  2020cites this paper
• Biallelic mutations in SORD cause a common and potentially treatable hereditary neuropathy with implications for diabetes

  2020cites this paper
• Clinician-rated measures for distal symmetrical axonal polyneuropathy

  2019cites this paper
• Recent Updates in Treatment of Diabetic Neuropathy

  2019cites this paper
• Diabetic neuropathy in children and adolescents with type 1 diabetes mellitus: Diagnosis, pathogenesis, and associated genetic markers

  2019cites this paper
• Regulatory Considerations for Early Clinical Development of Drugs for Diabetes, Obesity, Nonalcoholic Steatohepatitis (NASH) and Other Cardiometabolic Disorders

  2019cites this paper
• 3-Mercapto-5H-1,2,4-Triazino[5,6-b]Indole-5-Acetic Acid (Cemtirestat) Alleviates Symptoms of Peripheral Diabetic Neuropathy in Zucker Diabetic Fatty (ZDF) Rats: A Role of Aldose Reductase

  2019cites this paper
• Triglyceride-lowering effect of the aldose reductase inhibitor cemtirestat—another factor that may contribute to attenuation of symptoms of peripheral neuropathy in STZ-diabetic rats

  2019cites this paper
• Studies on the interaction mechanisms of Garcinia kolaviron constituents with selected diabetes and neurodegenerative disease targets

  2019cites this paper
• Peripheral Diabetic Neuropathies

  2019cites this paper
• The challenges of diabetic polyneuropathy: a brief update.

  2019cites this paper
• The aldose reductase inhibitor epalrestat exerts nephritic protection on diabetic nephropathy in db/db mice through metabolic modulation

  2018cites this paper
• Epalrestat, an Aldose Reductase Inhibitor, Restores Erectile Function in Streptozocin-induced Diabetic Rats

  2018cites this paper
• Aldo-Keto Reductases: Multifunctional Proteins as Therapeutic Targets in Diabetes and Inflammatory Disease.

  2018cites this paper
• Alpha‐lipoic acid for diabetic peripheral neuropathy.

  2018cites this paper
• How to prevent the microvascular complications of type 2 diabetes beyond glucose control

  2017cites this paper
• Diabetic neuropathy: Summary of treatment options

  2017cites this paper
• Predictors of response to treatment with actovegin for 6 months in patients with type 2 diabetes and symptomatic polyneuropathy.

  2017cites this paper
• Inhibition behaviours of some phenolic acids on rat kidney aldose reductase enzyme: an in vitro study

  2017cites this paper
• New Horizons in Diabetic Neuropathy: Mechanisms, Bioenergetics, and Pain.

  2017cites this paper
• Interventions for Neuropathic Pain: An Overview of Systematic Reviews

  2017cites this paper
• Neuropatia nei diabetici

  2017cites this paper
• Olive and ginkgo extracts as potential cataract therapy with differential inhibitory activity on aldose reductase.

  2017cites this paper
• Chapter 51 – Diabetes and Long-Term Complications

  2016cites this paper
• Characterization of Emodin as a Therapeutic Agent for Diabetic Cataract.

  2016cites this paper
• Effects of Pulsed Electromagnetic Field Therapy Versus Extra Corporeal Shock Wave Therapy on Peripheral Circulation and Functional Balance in Patients with Diabetic Peripheral Neuropathy: RCT

  2016cites this paper
• Does the blood glucose control have an effect on the success of the painful diabetic neuropathy treatment

  2016cites this paper
• Peripheral neuropathies.

  2016cites this paper
• Targeting Select Cellular Stress Pathways to Prevent Hyperglycemia-Related Complications: Shifting the Paradigm

  2016cites this paper
• A Role for Insulin in Diabetic Neuropathy

  2016cites this paper